Published in Science Translational Medicine, the research demonstrates that transplanted human V2a interneurons survived in the injured spinal cords of adult rats, integrated with the animals’ existing neural networks, and improved their ability to respond to respiratory stress. Interneurons are specialized cells that communicate between other neurons, helping coordinate complex functions such as movement and breathing. The findings provide a proof of principle that a defined population of human neurons can be manufactured, transplanted, and functionally incorporated into a damaged spinal circuit.

The research team focused on V2a interneurons, a class of spinal relay cells involved in motor control. These neurons participate in the communication pathways that connect the brainstem with the spinal networks responsible for coordinated muscle activity. Earlier studies had implicated V2a interneurons in recovery after traumatic spinal cord injury, including the neural circuits that regulate breathing and walking. The Gladstone researchers therefore reasoned that replacing some of these cells could strengthen damaged pathways rather than merely compensating for their loss through rehabilitation.

To produce the cells, the scientists developed a differentiation process that converts human induced pluripotent stem cells into transplantable spinal interneurons. Induced pluripotent stem cells can be generated by reprogramming mature adult cells into a flexible, stem-like state capable of producing many specialized cell types. The team refined molecular signals that guide these cells toward a V2a identity, then characterized the resulting neurons to confirm their developmental and functional properties. The cells were also prepared for cryopreservation, allowing them to be frozen, stored, thawed, and potentially standardized for future clinical manufacturing.

The work builds on nearly a decade of collaboration involving Lana Zholudeva, Michael Lane, Shelly Sakiyama-Elbert, Todd McDevitt, and other researchers. Early experiments used mouse embryonic stem cells to generate defined spinal neuron populations, while later efforts moved toward human induced pluripotent stem cell–derived therapies. According to the researchers, establishing a reliable recipe for producing the desired neurons required extensive trial and error. Creating a reproducible population that can be stored and administered later is considered essential for translating a cell-based treatment into a human clinical trial.

The researchers transplanted the human V2a interneurons into adult rats one week after cervical spinal cord injury. This region was selected because injuries to the neck can disrupt the respiratory circuitry that links the brainstem to the diaphragm. Two months after transplantation, the cells had survived within the hostile environment of the injured spinal cord and formed connections with neighboring host neurons. When the transplant region was experimentally activated, the animals showed increased diaphragm activity. Conversely, stimulation of the rats’ own brainstem neurons activated the transplanted human cells, indicating that the new neurons were receiving signals from the brain-to-spinal cord pathway.

Under ordinary conditions, the transplanted animals displayed only subtle differences in breathing compared with untreated injured rats. The distinction became much clearer when the animals were exposed to low oxygen or elevated carbon dioxide, challenges that force the respiratory system to increase its workload. Most untreated rats developed signs of respiratory failure under these conditions. In contrast, approximately three-quarters of the rats that received the V2a interneurons successfully tolerated the challenges. The result suggests that the transplanted cells may not restore normal breathing completely, but could provide additional functional reserve when the respiratory system is under stress.

The investigators also examined why some transplants appeared to perform better than others. Their analysis identified a subset of transplanted V2a interneurons that seemed especially likely to connect with the host breathing circuitry. These cells may possess molecular or anatomical features that make them more effective at forming synapses with surviving neurons. Understanding this variation could allow future therapies to be enriched for the most therapeutically useful cells, improving consistency and reducing the number of cells required for transplantation.

The study does not yet establish that the approach is safe or effective in people. Before human testing, the researchers must evaluate the therapy in larger animal models, examine long-term survival and circuit integration, and determine whether transplantation can help when treatment is delayed by months or years. They also need to investigate potential risks, including abnormal electrical activity, inappropriate connections, immune responses, and unintended cell behavior. The team is now exploring whether related spinal interneuron populations can be used to repair circuits controlling the arm and hand, functions that many people with cervical spinal cord injury consider their highest priority.

The findings mark a significant step in the effort to move spinal interneuron therapies from experimental stem cell models toward clinical translation. Rather than attempting to regenerate every damaged structure in the spinal cord, the strategy targets a specific circuit and supplies cells designed to restore missing communication links. If the results can be reproduced and made reliable across different injury patterns, engineered human neurons could eventually become part of a broader regenerative toolkit for spinal cord injury. For now, however, the work remains an early-stage demonstration in rats that carefully selected human cells can survive, form synaptic connections, and improve the physiological resilience of a damaged respiratory network.

Subject of Research: Human stem cell–derived spinal interneuron transplantation for repairing cervical spinal cord injury and restoring respiratory circuit function.

Article Title: Human spinal interneurons repair the injured rat spinal cord through synaptic integration

News Publication Date: 5-Aug-2026

Web References: Gladstone Institutes: https://gladstone.org/ ; Lana Zholudeva, PhD: https://gladstone.org/people/lana-zholudeva

References: Science Translational Medicine, DOI: https://doi.org/10.1126/scitranslmed.aea7461

Image Credits: Gladstone Institutes

Keywords: Spinal cord injury, stem cells, human induced pluripotent stem cells, V2a interneurons, spinal cord repair, regenerative medicine, neural circuits, respiratory function, synaptic integration, translational medicine

Ependymal cells, which line the central canal of the adult spinal cord, have intrigued neurobiologists for years due to their unique biology. Unlike many neural cell types locked into terminal differentiation, ependymal cells exhibit a remarkable plasticity upon injury, regaining characteristics akin to neural stem cells. Following SCI, they transiently proliferate and differentiate, but the endogenous response quickly wanes, leaving the spinal cord vulnerable to lasting deficits. The precise molecular cues orchestrating this activation, however, have remained elusive until now.

The latest findings emerge from a comprehensive study utilizing advanced genetic lineage tracing techniques in adult mice, focusing on the role of AMPA-type glutamate receptors (AMPARs)—key mediators of excitatory neurotransmission in the central nervous system. Previous work had hinted at AMPAR involvement in cultured epNSPCs, but the in vivo significance of this pathway was unclear. By selectively knocking out the GluA1, GluA2, and GluA3 subunits of AMPARs specifically in epNSPCs, the researchers demonstrated a profound impairment in glutamate-induced AMPA currents and, critically, a failure in the early activation of these cells after SCI.

This genetic deletion experiment underscored that AMPAR signaling is not merely a bystander but a driver of the neural stem/progenitor cell response to injury. The loss of AMPAR-mediated currents effectively silences the ependymal cells’ alarm system, preventing them from mounting an initial regenerative effort. Such insights reframed our understanding of neurotransmitter receptors beyond their classical roles in synaptic transmission, positioning them as central players in cellular responses to injury.

Capitalizing on this knowledge, the study explored pharmacological enhancement of AMPAR activity using an ampakine compound known as CX546. Ampakines are positive allosteric modulators that enhance AMPAR-mediated signaling without directly activating the receptor, thereby fine-tuning excitatory neurotransmission. Treatment with CX546 after SCI prolonged the epNSPCs’ immature, stem-like state well into the chronic phase of injury, a remarkable extension beyond their usual transient activation window.

At the transcriptional level, CX546 treatment precipitated a shift in gene expression profiles of the epNSPCs, reinforcing pathways associated with cellular migration, proliferation, and intercellular communication. Among the most notable effects was the upregulation of connexin-43, a protein integral to gap junction formation and astrocytic communication. This molecular change appeared to facilitate enhanced contact between ependymal-derived cells and glial neighbors, potentially creating a more favorable microenvironment for cell migration and coordination within the injured spinal cord milieu.

The increased migratory capacity of epNSPCs following CX546 administration marked a pivotal advance. Instead of remaining confined near the central canal, these cells demonstrated augmented spatial distribution across lesion sites, a phenomenon likely instrumental to tissue repair. The ability of these endogenous progenitors to navigate the complex architecture of injured spinal tissue and reach areas of denervation suggests that modulating AMPAR signaling could harness intrinsic repair mechanisms more effectively.

Beyond cellular and molecular effects, the functional consequences of AMPAR enhancement were equally compelling. CX546 treatment mitigated the subacute decline in corticospinal tract excitability, a critical neural pathway responsible for voluntary motor control. Preservation and restoration of this excitability translated into tangible long-term improvements in motor function in treated mice, a promising indicator for future translational therapies.

Mechanistically, the findings support a model in which excessive glutamate release following SCI, traditionally viewed as deleterious excitotoxicity, paradoxically initiates a regenerative signaling cascade via AMPAR activation on epNSPCs. This discovery reframes glutamate dynamics post-injury, highlighting a dual role for excitatory neurotransmission in both injury and repair. The capacity to selectively amplify this beneficial pathway without exacerbating toxicity presents a nuanced therapeutic avenue.

The study also challenges existing dogma regarding the limited regenerative capability of the adult central nervous system. By elucidating how a neurotransmitter receptor modulates the stem/progenitor cell niche in the spinal cord, it opens the door to novel strategies aimed at endogenous cell populations rather than relying solely on exogenous cell transplantation or biomaterial scaffolds. This receptor-dependent mechanism provides a biologically elegant means of stimulating repair processes that are often dormant in mature tissue.

Importantly, the use of CX546—a compound already known for its cognitive-enhancing properties in other neurological contexts—accelerates the translational potential of these findings. Ampakines’ established safety profile may facilitate their repurposing for SCI, streamlining the path to clinical trials. Additionally, fine-tuning the timing and dosing of AMPAR modulation could maximize regenerative outcomes while minimizing risks associated with altered excitatory signaling.

The implications of this research extend beyond spinal cord injuries. AMPAR-dependent regulation of neural progenitors may also influence other neurodegenerative conditions where endogenous repair is insufficient. Understanding how neurotransmitter receptors interface with adult stem cell biology could revolutionize regenerative medicine, fostering new treatments for stroke, traumatic brain injury, and demyelinating diseases.

This study exemplifies the power of integrating molecular genetics, electrophysiology, pharmacology, and functional assessments to unravel complex neurobiological processes. By connecting receptor-level activity to stem cell behavior and ultimately to organism-level recovery, it bridges fundamental neuroscience with translational aspirations—a rare and valuable achievement in the field.

Looking ahead, further studies will need to dissect the long-term fate of epNSPCs activated via AMPAR signaling, including their differentiation potential and integration into neural circuits. Moreover, unraveling how AMPAR subunit composition affects these dynamics could yield even more precise therapeutic targets. The interplay between gap junction communication and migration also warrants deeper exploration to harness synergistic mechanisms of repair.

In sum, this landmark research highlights a previously underappreciated role of glutamate signaling in modulating endogenous stem/progenitor cell responses to spinal cord injury. Through enhancing AMPAR activity, it is now possible to sustain and optimize the regenerative capacity of ependymal cells in the adult spinal cord, driving functional improvements that were once deemed unattainable. Such advances inject renewed optimism into the field, inspiring a new wave of innovative approaches to neurorepair grounded firmly in the biology of the spinal cord itself.

Subject of Research: Ependymal-derived neural stem/progenitor cells and AMPA receptor signaling in spinal cord injury repair.

Article Title: Augmenting AMPA receptor signaling after spinal cord injury increases ependymal-derived neural stem/progenitor cell migration and promotes functional recovery.

Article References:
Hachem, L.D., Moradi Chameh, H., Balbinot, G. et al. Augmenting AMPA receptor signaling after spinal cord injury increases ependymal-derived neural stem/progenitor cell migration and promotes functional recovery. Nat Neurosci (2025). https://doi.org/10.1038/s41593-025-02044-8

Image Credits: AI Generated

At the heart of this revelation lies the enzyme monoamine oxidase B (MAOB), expressed in astrocytes—the star-shaped glial cells within the spinal cord. MAOB drives the aberrant production of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter whose excess presence effectively “brakes” the regenerative processes. Unlike the traditionally understood glial scar or barrier, which physically obstructs axonal regrowth, this MAOB–GABA axis works at the molecular level, suppressing critical growth factor signaling pathways necessary for neural repair. By dampening these reparative signals, the brain-to-body communication pathway remains severed, leaving patients with chronic disabilities.

The study, led by Director C. Justin Lee of the Institute for Basic Science (IBS) alongside collaborators at Yonsei University College of Medicine, meticulously elucidated the biochemical cascade in a series of sophisticated animal models. They demonstrated that the surplus GABA produced by reactive astrocytes represses the expression of brain-derived neurotrophic factor (BDNF) and its receptor TrkB—both essential mediators of neuronal survival and axonal proliferation. Without adequate BDNF signaling, injured neurons lack the impetus to regrow, resulting in permanent functional impairment.

This discovery represents a paradigm shift, moving beyond the simplistic notion that neural recovery is hindered solely by structural impediments to address the subtle, molecular forms of inhibition. Previous therapeutic strategies largely focused on mitigating inflammation or alleviating secondary symptoms, with limited longevity or efficacy in functional restoration. The MAOB–GABA axis emerges not just as a contributor but as a central regulator impeding spinal cord regeneration, redefining the biological framework underpinning axonal repair failure.

To confirm the pivotal role of MAOB in this pathological mechanism, the research team employed genetic and pharmacological manipulations in rodent models. Suppression of MAOB within spinal astrocytes led to marked axonal regrowth and recovery of hindlimb motor function, while enhanced MAOB expression exacerbated tissue damage and functional loss. These results underscore the critical, direct link between MAOB activity and the inhibition of structural and behavioral recovery following spinal cord injury.

Capitalizing on these insights, the researchers turned to KDS2010, a selective and reversible MAOB inhibitor with prior validation of safety in Phase I clinical trials involving healthy individuals. Administration of KDS2010 in spinal cord-injured animals profoundly improved locomotor abilities and neurological outcomes. Behavioral assessments recorded fewer hindlimb slips during ladder-walking tasks, reflecting restored motor coordination. Histological evaluation corroborated these findings, showing reduced lesion sizes and increased remyelination of axons, which is crucial for electrical signal conduction and neuronal function.

Strikingly, these therapeutic benefits extended beyond rodent models into non-human primates, where KDS2010 treatment similarly preserved spinal tissue integrity and enhanced neural protection. The cross-species efficacy strengthens the translational potential of this treatment, bridging the gap between laboratory studies and human clinical applicability. The capacity of KDS2010 to modulate the astrocytic MAOB–GABA axis introduces a novel, mechanism-based intervention that directly targets neural regeneration pathways.

“This study identifies a fundamental molecular brake on spinal cord repair and offers a targeted strategy to overcome this obstacle,” explained Director C. Justin Lee. “By focusing on the inhibition of MAOB, we can lift the biochemical ‘brake’ imposed by GABA, facilitating the reconnection of neural circuits essential for motor recovery.” Such an approach contrasts sharply with existing symptom-based therapies, promising a transformative impact on patient outcomes.

Professor Ha Yoon of Yonsei University College of Medicine emphasized the clinical promise of these findings: “Given KDS2010’s proven safety profile in Phase I trials, the next logical step is to advance towards Phase II studies focused on spinal cord injury patients. Moreover, the broader implications of MAOB-mediated GABA release in other neurological conditions are compelling and could open new avenues for treatment development.” This prospect positions the MAOB–GABA pathway not only as a target for spinal repair but as a potential cornerstone in treating a spectrum of neurodegenerative and neurotraumatic disorders.

The investigation leveraged multi-institutional collaboration, integrating biochemistry, neurobiology, and translational medicine from research centers including IBS, Yonsei University, Seoul National University, and the Korea Institute of Science and Technology (KIST), supported by Korea’s Ministry of Science and ICT and the National Research Foundation. Published in the prestigious journal Signal Transduction and Targeted Therapy, the work highlights the impactful convergence of basic research and clinical innovation, with a high journal impact factor reflecting its significance.

This research challenges long-held assumptions about the limited capacity for spinal cord regeneration and opens a promising therapeutic horizon. By elucidating the molecular machinery of repair inhibition and demonstrating a safe, effective means to counteract it, the study galvanizes hope for millions worldwide affected by spinal cord injuries. The therapeutic inhibition of MAOB with agents such as KDS2010 represents a precise, targeted intervention poised to reshape neurorehabilitation.

Continuing efforts will focus on further dissecting the intricate signaling networks downstream of GABA-mediated inhibition and refining MAOB inhibitors’ pharmacodynamics and pharmacokinetics. Understanding whether similar mechanisms operate in other central nervous system injuries or neurodegenerative contexts could expand the clinical impact of this discovery. As the field moves toward clinical trials, it is imperative to monitor efficacy while assessing long-term functional recovery and potential neurological side effects.

In summary, this research illuminates a critical molecular barrier previously obscured in spinal cord injury pathology. Targeting the astrocytic MAOB–GABA axis offers a compelling new strategy to unlock neural regeneration, restore motor function, and ultimately improve quality of life for patients globally. The advent of KDS2010 heralds a new era of precision medicine in spinal cord injury, transforming decades of scientific insight into tangible therapeutic breakthroughs.

Subject of Research: Animals
Article Title: Astrocytic monoamine oxidase B (MAOB)–gamma-aminobutyric acid (GABA) axis as a molecular brake on repair following spinal cord injury
News Publication Date: 10-Sep-2025
Web References: http://dx.doi.org/10.1038/s41392-025-02398-2
Image Credits: Institute for Basic Science
Keywords: Spinal cord injuries, Nerve injuries, Traumatic injury, Diseases and disorders, Astrocytes, Glia, Cells, Cell biology, Life sciences, GABA, Neurotransmitters, Neurochemistry, Biochemistry, Inflammation, Symptomatology